Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin timing and placental transfusion in term infants
NCT02618499Phase 3Terminated
- Sponsor
- FUNDASAMIN
- Start
- May 2016
- Primary completion
- Nov 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxytocin in postpartum hemorrhage (PPH) and anemia, sponsored by FUNDASAMIN. Primary endpoint: Placental transfusion volume at 3 months. Started May 2016; status: terminated.
02
Drugs
oxytocin
03
Conditions
postpartum hemorrhage (PPH)anemia
Beyond the preview
Go deeper on NCT02618499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02618499.